Clinical Trial Update: CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating CPI-613 in advanced or metastatic biliary tract cancers, including cholangiocarcinoma and unresectable or metastatic liver/b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Cholangiocarcinoma
• Extrahepatic Bile Duct Cancer
• Gallbladder Cancer
• Liver Cancer

Drugs mentioned

• CPI-613 (devimistat)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-05-15